Show simple item record

dc.contributor.authorLe Couteur, David Gen
dc.contributor.authorBateman, Braceen
dc.contributor.authorBrayne, Carolen
dc.date.accessioned2018-06-21T14:59:19Z
dc.date.available2018-06-21T14:59:19Z
dc.date.issued2018-02-21en
dc.identifier.issn0959-8146
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/277353
dc.description.abstractThis has already been a disheartening year for research into drug treatments for dementia and Alzheimer’s disease. Negative results have been posted for phase III clinical trials of two 5-hydroxytryptamine-6 receptor (5-HT6) antagonists for the symptomatic treatment of moderate dementia;1 2 and another trial of an amyloid-beta antibody as a disease-modifying treatment in mild dementia.3 Pfizer announced that it will end its neuroscience and related dementia investments in drug development, removing a major industry partner from the field.4
dc.format.mediumElectronicen
dc.languageengen
dc.subjectHumansen
dc.subjectDementiaen
dc.subjectBenzylaminesen
dc.subjectIndolesen
dc.subjectSerotonin Antagonistsen
dc.subjectTreatment Failureen
dc.subjectClinical Trials as Topicen
dc.titleIdalopirdine: another disappointment for people with dementia.en
dc.typeArticle
prism.publicationDate2018en
prism.publicationNameBMJ (Clinical research ed.)en
prism.startingPagek753
prism.volume360en
dc.identifier.doi10.17863/CAM.24649
dcterms.dateAccepted2018-02-15en
rioxxterms.versionofrecord10.1136/bmj.k753en
rioxxterms.versionAM*
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-02-21en
dc.contributor.orcidBrayne, Carol [0000-0001-5307-663X]
dc.identifier.eissn1756-1833
rioxxterms.typeJournal Article/Reviewen
rioxxterms.freetoread.startdate2019-02-21


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record